Printer Friendly

Articles from M2 Pharma (June 3, 2019)

1-23 out of 23 article(s)
Title Author Type Words
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension. 708
ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors. 455
BioInvent submits IND with US FDA for Phase I/IIa trial of anti-FcI[superscript three]RIIB antibody. 248
Cantargia announces presentation of phase I clinical data on antibody CAN04 at ASCO Annual Meeting. 294
Carisma Therapeutics names new chief scientific officer. 258
Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019. Clinical report 654
Episurf Medical reports on conversion of convertible bonds. 161
Erleada Significantly Improved Overall Survival and Radiographic Progression-Free Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer. 239
Ethris names Thomas Langenickel, MD as CMO. 150
Expanded Rubraca Data from Clovis Oncology's ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers Presented at 2019 ASCO Annual Meeting. 1045
Five-Year Survival Data for US Merck's Keytruda in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting. 679
Lantheus Holdings collaborates with NanoMab Technology. 166
Lyndra Therapeutics elects Patricia Hurter as CEO to strengthen development capabilities. 177
Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of Darzalex Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma. 199
Qkine announces additional GBP550,000 from funding round. 138
Reviva Pharmaceuticals updates results of Pre-IND meeting with US FDA for Brilaroxazine for Idiopathic Pulmonary Fibrosis. 243
Spectrum Pharmaceuticals Presents Integrated Results from Two Phase 3 Rolontis Trials Being Presented at the ASCO Annual Meeting. 192
Study Investigating Darzalex Shows Improved Depth of Response and Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant. 217
Taiwan Food and Drug Administration receives new drug application for CStone Pharmaceuticals' TIBSOVO. 204
US FDA receives Epizyme's new drug application for Tazemetostat accelerated approval. 180
US Merck's Keytruda Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial. 383
Vertex Pharmaceuticals selects VX-445 triple combination to submit for global regulatory approvals. 216
WAT Medical to market EmeTerm and HeadaTerm in Australia following TGA Australia's approval. 268

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |